BiotechTube
HeartStitch

HeartStitch

Menlo Park, United States· Est.
heartstitch.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $105M

Overview

HeartStitch is a clinical-stage medical device innovator targeting the large and growing market for minimally invasive structural heart procedures. Its core technology platform centers on proprietary suture delivery systems designed to facilitate complex transcatheter and endoscopic suturing, particularly for mitral and tricuspid valve repair. The company is advancing its lead product, the FELIX system, through clinical trials, positioning itself in a competitive but high-reward segment of the cardiology device space. As a private company, it has secured venture funding to progress its pipeline and seeks to address significant unmet needs in valvular heart disease.

Cardiovascular

Technology Platform

Proprietary suture delivery platform for minimally invasive and transcatheter cardiac surgery, enabling remote suturing and fixation in structural heart procedures.

Funding History

2
Total raised:$105M
Series B$75M
Series A$30M

Opportunities

The large and growing patient population with valvular heart disease, especially high-risk patients ineligible for surgery, creates a significant addressable market.
The trend toward minimally invasive procedures and the nascent, high-growth state of the tricuspid repair market present substantial expansion opportunities.
Successful technology validation could position the company as an attractive acquisition target for major medtech firms.

Risk Factors

The company faces intense competition from well-established medical device giants with extensive resources and commercial reach.
Clinical development risks include potential failure to demonstrate safety or efficacy in trials, and regulatory pathways for novel devices can be lengthy and uncertain.
Market adoption risks include physician training requirements and securing adequate reimbursement from payers.

Competitive Landscape

HeartStitch competes in the dynamic structural heart device market against dominant players like Abbott (MitraClip, TriClip), Edwards Lifesciences (PASCAL, Cardioband), and Medtronic, as well as numerous private ventures. Competition is based on clinical efficacy, procedural ease, physician training, and commercial support. The company's niche is its focus on solving the transcatheter suturing challenge, differentiating it from clip-based and ring-based competitors.

More companies in Drug Delivery & Formulation →More companies in United States →